Arboleda–Tham Syndrome (KAT6A Syndrome): Comprehensive Disease-Characteristics Report

Executive summary

Arboleda–Tham syndrome (ARTHS), more commonly called KAT6A syndrome, is a rare autosomal-dominant Mendelian chromatinopathy caused by heterozygous pathogenic variants in KAT6A, a lysine acetyltransferase and transcriptional regulator. The defining phenotype is congenital or early-childhood neurodevelopmental impairment—particularly severe expressive speech delay—with variable hypotonia, feeding and gastrointestinal dysfunction, characteristic craniofacial features, eye abnormalities, congenital heart disease, microcephaly, growth impairment, sleep disturbance, behavioral differences, and occasional seizures. Most affected individuals have a de novo protein-truncating variant; late truncations in exons 16–17 tend to produce a more severe phenotype than earlier truncations. The best available cohort contained 76 individuals aged 1–32 years, so population prevalence, adult natural history, life expectancy, and formal quality-of-life outcomes remain poorly defined. (kennedy2019kat6asyndromegenotype–phenotype pages 8-9, kennedy2019kat6asyndromegenotype–phenotype pages 1-2)

The strongest recent mechanistic advance is a 2024 mouse study identifying a KAT6A→RSPO2→Wnt/β-catenin pathway in hippocampal CA3 pyramidal neurons. Kat6a deficiency reduced CA3 synaptic structure and plasticity and impaired memory; AAV-mediated restoration of RSPO2 substantially rescued the molecular, synaptic, and behavioral deficits. This is important proof of biological reversibility but not yet a human treatment. (liu2024kat6adeficiencyimpairs pages 8-9, liu2024kat6adeficiencyimpairs pages 1-2)

The following compact table summarizes high-yield knowledge-base annotations; ontology mappings are suggestions and should be validated against the release used by the target database.

Table: This table compiles the highest-yield, evidence-backed annotations for Arboleda-Tham/KAT6A syndrome using only the information gathered in the preceding search. It is useful as a compact knowledge-base scaffold spanning identifiers, phenotype frequencies, mechanism, diagnostics, management, and evidence gaps.

1. Disease information

Definition and identifiers

• Preferred names: Arboleda–Tham syndrome; KAT6A syndrome.
• Alternative names: autosomal dominant intellectual disability–craniofacial anomalies–cardiac defects syndrome; autosomal dominant mental retardation 32; KAT6A-related neurodevelopmental disorder.
• MONDO: MONDO:0014558, represented as autosomal dominant intellectual disability–craniofacial anomalies–cardiac defects syndrome.
• OMIM phenotype: 616268.
• Causal gene: KAT6A, OMIM gene 601408, also known as MOZ and MYST3; Ensembl target ENSG00000083168.
• Chromosomal location: 8p11.21/8p11 region.
• ICD-10/ICD-11 and MeSH: no syndrome-specific code or descriptor was established in the retrieved evidence. Coding generally must use broader congenital-malformation, intellectual-disability, or genetic-syndrome categories. (OpenTargets Search: Arboleda-Tham syndrome-KAT6A, bae2021identificationofa pages 1-2, lin2020diagnosisofarboledatham pages 3-4)

The syndrome was delineated in 2015 after clinical trio-exome sequencing identified de novo heterozygous nonsense variants in four unrelated families. The discovery abstract states: “Common features among all four probands include primary microcephaly, global developmental delay including profound speech delay, and craniofacial dysmorphism.” [Arboleda et al., published March 5, 2015; DOI: https://doi.org/10.1016/j.ajhg.2015.01.017]. (arboleda2015denovononsense pages 1-2)

Evidence provenance

The evidence is principally aggregated disease-level information derived from individually ascertained patients, including clinician reports, family surveys, case reports, exome/genome cohorts, and literature review. It is not based on a population registry or systematic extraction from longitudinal electronic health records. The largest study combined 52 new cases with previously published individuals for a total of 76. (kennedy2019kat6asyndromegenotype–phenotype pages 1-2)

2. Etiology

Causal and genetic risk factors

ARTHS is caused by a heterozygous constitutional pathogenic variant in KAT6A. Most reported variants are nonsense or frameshift alleles, although splice-site and selected missense variants have also been described. In the 2019 cohort, 39/44 novel variants (88%) were predicted truncating. Recurrent nonsense hotspots at amino-acid positions 1019, 1024, and 1129 accounted for 13/68 (19.1%) pathogenic variants among unrelated individuals. (kennedy2019kat6asyndromegenotype–phenotype pages 8-9, kennedy2019kat6asyndromegenotype–phenotype pages 2-3)

Examples include:

• NM_006766.5:c.3385C>T, p.Arg1129Ter, recurrent in the discovery series;
• c.3070C>T, p.Arg1024Ter;
• NM_006766.5:c.3411del, p.Glu1139SerfsTer41, a de novo exon-17 variant associated with severe delay;
• c.1312C>T, p.Arg438Ter, an early truncating variant expected to undergo nonsense-mediated decay;
• c.3427_3428insTA, p.Ser1143LeufsTer5;
• c.1075G>A, p.Gly359Ser, which experimentally altered splicing rather than acting solely as a missense allele. (bae2021identificationofa pages 1-2, lin2020diagnosisofarboledatham pages 3-4, urreizti2020fivenewcases pages 7-8, arboleda2015denovononsense pages 1-2)

Pathogenic constitutional variants are expected to be absent or extremely rare from population databases because of strong functional constraint and severe early-onset effects. Exact gnomAD/TOPMed frequencies were not available in the retrieved texts and should be obtained variant-by-variant rather than inferred.

Environmental, infectious, and lifestyle risk factors

No toxin, infection, radiation, diet, smoking, alcohol, occupation, or other lifestyle exposure is known to cause ARTHS. It is not infectious or environmentally acquired. Phenotypic variability may reflect genetic background, epigenetic state, development, clinical ascertainment, and possibly environment, but no reproducible gene–environment interaction has been demonstrated. The 2019 cohort explicitly considered background genetic variation and environmental factors plausible contributors to expressivity, not established causal exposures. (kennedy2019kat6asyndromegenotype–phenotype pages 9-10, arboleda2015denovononsense pages 6-7)

Protective factors and modifiers

No validated protective allele, modifier gene, diet, or exposure is known. KAT6B may provide partial biochemical redundancy in some tissues, but this is mechanistic inference rather than a clinically established modifier. Pantothenate and L-carnitine improved cellular abnormalities in vitro; they have not been shown to prevent disease or improve outcomes in patients. (munueracabeza2022pantothenateandlcarnitine pages 1-2, liu2024kat6adeficiencyimpairs pages 8-9)

3. Phenotypes

The most reusable frequencies come from the 76-person cohort and the subsequent synthesis of approximately 80 reported cases. Denominators vary because not every feature was assessed in every patient; percentages should therefore be stored with study provenance rather than treated as population penetrance. (urreizti2020fivenewcases pages 7-8, kennedy2019kat6asyndromegenotype–phenotype pages 1-2)

These estimates are supported by the five-case/literature synthesis reporting developmental delay/ID 100%, speech delay 99%, feeding difficulty 79%, neonatal hypotonia 74%, ear anomalies 83%, eye anomalies 72%, microcephaly 36%, seizures 13%, and sleep disturbance 42%. (urreizti2020fivenewcases pages 7-8) Congenital heart disease occurs in approximately half, and feeding difficulties were estimated at 78.7% in another review. (bae2021identificationofa pages 5-6, kennedy2019kat6asyndromegenotype–phenotype pages 6-7)

Quality of life

No validated ARTHS-specific EQ-5D, SF-36, PROMIS, or caregiver-burden dataset was identified. The major inferred burdens are impaired communication, intellectual and adaptive limitations, feeding support, constipation, visual disability, sleep disruption, mobility problems, and repeated specialty care. Communication aids and early speech therapy are therefore clinically important even in the absence of controlled quality-of-life trials. (bae2021identificationofa pages 6-7, kennedy2019kat6asyndromegenotype–phenotype pages 6-7)

4. Genetic and molecular information

Gene and protein

KAT6A encodes a roughly 250-kDa MYST-family lysine acetyltransferase. Important regions include an N-terminal NEMM/winged-helix region, a double PHD finger, the catalytic histone-acetyltransferase domain, and long acidic and serine/methionine-rich C-terminal regions. KAT6A operates in multiprotein chromatin complexes with BRPF-family scaffolds, ING4/ING5, and MEAF6/EAF6-associated components. It modifies histone and non-histone substrates, including p53. (arboleda2015denovononsense pages 6-7, weber2023thehistoneacetyltransferase pages 1-2)

Variant classes and consequences

• Early truncating variants, exons 1–15: commonly expected to trigger nonsense-mediated mRNA decay and produce haploinsufficiency.
• Late truncating variants, exons 16–17: may escape nonsense-mediated decay, leaving truncated proteins with altered C-terminal regulatory functions. The cohort association with greater severity raises dominant-negative or altered-function possibilities, but these mechanisms are not fully proven in patients.
• Canonical splice variants: pathogenic when demonstrated to disrupt splicing.
• Missense variants: require cautious evaluation. De novo status, absence from population databases, domain/residue conservation, phenotype concordance, functional evidence, and an ARTHS-compatible methylation signature can strengthen classification. A maternally inherited p.Ser371Tyr allele was classified as a VUS in the 2019 study. (kennedy2019kat6asyndromegenotype–phenotype pages 8-9, kennedy2019kat6asyndromegenotype–phenotype pages 2-3, liu2024kat6adeficiencyimpairs pages 1-2)

Variants causing the developmental syndrome are germline/constitutional, not somatic. Somatic KAT6A rearrangements or fusions are relevant to leukemia but are a separate disease mechanism and should not be conflated with ARTHS.

Genotype–phenotype relationship

Late truncations in exons 16–17 correlate with more severe intellectual disability, speech impairment, microcephaly, neonatal hypotonia, cardiac anomalies, and gastrointestinal complications. Early truncations may have fewer gastrointestinal manifestations. This is a group-level association, not a deterministic prognostic rule. (bae2021identificationofa pages 1-2, bae2021identificationofa pages 5-6, kennedy2019kat6asyndromegenotype–phenotype pages 8-9)

Epigenetics and chromosomal abnormalities

The syndrome is itself an epigenetic-regulator disorder. Patient fibroblasts showed reduced H3K9 acetylation and increased H3K18 acetylation in the original study, with altered p53-pathway expression. A later cellular study also found reduced histone-H3 acetylation, broad transcriptomic disturbance, and mitochondrial/bioenergetic abnormalities. (munueracabeza2022pantothenateandlcarnitine pages 15-16, arboleda2015denovononsense pages 6-7)

A 2023 publication reported sensitive and specific blood DNA-methylation episignatures for KAT6A/KAT6B variants, suggesting a future adjunct for VUS interpretation; however, the full study was not retrievable in this search, so assay performance should be verified directly before database entry or clinical use [Vos et al., Epigenomics, May 2023; DOI: https://doi.org/10.2217/epi-2023-0079].

No recurrent pathogenic aneuploidy, translocation, inversion, or syndrome-defining copy-number alteration is established as the usual cause. Deletions disrupting KAT6A could theoretically cause haploinsufficiency, but larger 8p alterations may produce blended phenotypes.

5. Environmental information

No environmental toxin, radiation exposure, pollutant, occupational factor, lifestyle behavior, or infectious agent is known to initiate ARTHS. Standard healthy diet, activity, vaccination, and avoidance of tobacco exposure remain appropriate general health measures but are not disease-specific prevention. Nutrient-dependent acetyl-CoA and mitochondrial biology may influence cellular acetylation, yet no clinical evidence establishes diet as a modifier of penetrance or severity. (munueracabeza2022pantothenateandlcarnitine pages 1-2, munueracabeza2022pantothenateandlcarnitine pages 15-16)

6. Mechanism and pathophysiology

Upstream molecular lesion

A pathogenic KAT6A allele reduces the amount of functional enzyme or yields a C-terminally truncated dysfunctional protein. KAT6A normally binds chromatin and catalyzes lysine acetylation, helping establish transcriptionally competent chromatin. A 2023 biochemical study showed that an N-terminal winged-helix domain directly recognizes unmethylated CpG motifs and recruits KAT6A to CpG islands genome-wide. Mutating essential DNA-binding residues abolished CpG-island enrichment; a winged-helix mutant also exerted a dominant-negative effect on H3K9 acetylation. (weber2023thehistoneacetyltransferase pages 1-2)

Downstream chromatin and cellular effects

The original patient-fibroblast study found altered H3K9/H3K18 acetylation and differential expression of 30 p53-pathway genes, enriched for apoptosis, transcriptional regulation, and metabolism. The authors concluded that KAT6A variants alter global acetylation and p53-mediated pathways. (arboleda2015denovononsense pages 6-7)

Fibroblasts from three patients subsequently showed reduced H3 acetylation and reduced proteins involved in acetylation/deacetylation, CoA metabolism, mitochondrial function, and antioxidant defense, including SIRT1, SIRT3, NAMPT, PANK2, mitochondrial respiratory-chain proteins, SOD1/SOD2, and GPX4. These findings support secondary mitochondrial and redox dysfunction, but fibroblasts are a surrogate model and do not establish that every abnormality occurs in human neurons or heart tissue. (munueracabeza2022pantothenateandlcarnitine pages 1-2, munueracabeza2022pantothenateandlcarnitine pages 15-16)

KAT6A–RSPO2–Wnt causal chain in the brain

The best-defined neural mechanism is:

KAT6A haploinsufficiency → reduced H3K23 acetylation at the Rspo2 promoter and reduced Rspo2 transcription → diminished RSPO2-dependent canonical Wnt/β-catenin signaling → reduced dendritic-spine density, excitatory transmission, and long-term potentiation in CA3 pyramidal neurons → impaired hippocampus-dependent learning and memory.

Single-nucleus RNA sequencing and chromatin analysis identified Rspo2 as the robust CA3-enriched transcriptional target. Excitatory-neuron Rspo2 deletion phenocopied Kat6a loss, whereas AAV-RSPO2 delivery restored β-catenin, synaptic physiology, dendritic spines, and much of the learning/memory phenotype. CA1 synaptic function was comparatively spared. (liu2024kat6adeficiencyimpairs pages 8-9, liu2024kat6adeficiencyimpairs pages 1-2)

Direct abstract quote: “Deletion of Rspo2 in excitatory neurons impairs memory formation, and restoring RSPO2 expression in CA3 neurons rescues the deficits in Wnt signaling and learning-associated behaviors in Kat6a mutant mice.” [Liu et al., Science Advances, May 17, 2024; DOI: https://doi.org/10.1126/sciadv.adm9326]. (liu2024kat6adeficiencyimpairs pages 1-2)

Suggested ontologies

• GO biological process: histone acetylation; chromatin organization; regulation of transcription by RNA polymerase II; canonical Wnt signaling; synaptic plasticity; learning or memory; stem-cell maintenance; embryonic organ development.
• GO cellular component: nucleus; chromatin; histone acetyltransferase complex; neuronal dendrite; excitatory synapse.
• Cell Ontology: fibroblast; excitatory neuron; pyramidal neuron; hippocampal CA3 pyramidal neuron where an exact release-specific term exists; hematopoietic stem cell; neural-crest-derived craniofacial cell as a proposed developmental annotation.

Omics and advanced technologies

Human fibroblast RNA-seq demonstrated transcriptomic disturbance; the 2024 mouse study integrated single-nucleus RNA-seq with chromatin analysis. No validated human disease-specific proteomic, metabolomic, lipidomic, spatial-transcriptomic, organoid, or large iPSC atlas was identified. No published therapeutic CRISPR screen was retrieved. (munueracabeza2022pantothenateandlcarnitine pages 1-2, liu2024kat6adeficiencyimpairs pages 1-2, arboleda2015denovononsense pages 6-7)

7. Anatomical structures affected

• Primary nervous-system involvement: developing brain and neural circuits governing cognition, speech, language, motor planning, tone, sleep, and behavior. The strongest mechanistic localization is hippocampal CA3, not evidence that disease is restricted to CA3.
• Cardiovascular: atrial/ventricular septa, ductus arteriosus, and other congenital cardiac structures.
• Gastrointestinal/oromotor: oral and pharyngeal feeding apparatus, esophagus, bowel motility, and occasionally intestinal rotation/obstruction.
• Craniofacial: skull, palate, midface, nose, lips, jaw, and external ears.
• Eye: extraocular alignment and visual system; ptosis and structural ocular abnormalities occur variably.
• Musculoskeletal: spine, feet, joints, and cranial sutures in a subset.
• Genitourinary: testes/inguinal region in some males.
• Hematopoietic/immune system: major defects occur in complete mouse knockouts; recurrent infection and an isolated 2023 marrow-failure report warrant awareness, but routine human hematopoietic failure is not established. (lin2020diagnosisofarboledatham pages 3-4, urreizti2020fivenewcases pages 7-8, kennedy2019kat6asyndromegenotype–phenotype pages 6-7, arboleda2015denovononsense pages 6-7)

Suggested UBERON annotations include brain, hippocampus, CA3 field of hippocampus, heart, gastrointestinal tract, eye, palate, craniofacial skeleton, spinal column, and testis. Relevant subcellular annotations are nucleus, chromatin, nucleosome, and histone-acetyltransferase complex. No consistent lateralization is known.

8. Temporal development

ARTHS begins prenatally through disturbed embryonic gene regulation, although the neurodevelopmental phenotype often becomes clinically apparent in infancy. Congenital manifestations can include craniofacial differences, heart defects, palate abnormalities, hypotonia, feeding difficulty, growth restriction, and microcephaly. Developmental and especially expressive-language delays become clearer over the first years; an infant diagnosed at two months developed evident expressive-language delay by eight months. (bae2021identificationofa pages 1-2, bae2021identificationofa pages 6-7)

The disorder is chronic and lifelong. It has no accepted staging system, relapsing-remitting pattern, or spontaneous remission phenotype. Congenital structural abnormalities are generally stable or surgically corrected, while development continues slowly with variable gains. Constipation, sleep problems, orthopedic abnormalities, and communication disability may remain chronic. One individual had progressive cerebellar atrophy, but progressive neurodegeneration is not established as the typical course. (urreizti2020fivenewcases pages 7-8)

Early childhood is the principal intervention window for feeding safety, communication, motor development, vision, and cardiac assessment. Early genomic diagnosis therefore has practical value even without disease-modifying therapy. (bae2021identificationofa pages 6-7, kennedy2019kat6asyndromegenotype–phenotype pages 6-7)

9. Inheritance and population

Inheritance is autosomal dominant and usually de novo. For an affected individual with a constitutional pathogenic variant, the theoretical transmission risk is 50% per pregnancy, although reproductive fitness and individual circumstances vary. Parents testing negative in blood usually have a low recurrence risk, but parental germline or low-level somatic mosaicism cannot be excluded; no syndrome-specific mosaic recurrence rate is available.

Penetrance appears high for truncating pathogenic variants ascertained clinically, while expressivity is markedly variable. Missense alleles require greater caution because incomplete penetrance, alternate molecular effects, or misclassification may occur. Genetic anticipation is not expected because ARTHS is not a repeat-expansion disorder. Consanguinity is not etiologically relevant to a predominantly de novo dominant condition. No founder variant, carrier frequency, or population-specific enrichment is established. (kennedy2019kat6asyndromegenotype–phenotype pages 8-9, kennedy2019kat6asyndromegenotype–phenotype pages 2-3, kennedy2019kat6asyndromegenotype–phenotype pages 9-10)

The largest cohort included 76 individuals aged 1–32 years and was sex-balanced: 49% female and 51% male. Cases have been reported across multiple ancestries and regions; no geographic or ethnic predilection is established. Approximately 400–500 diagnosed patients had been cited by 2023–2024 mechanistic publications, but this is a reported-case count, not prevalence. A discovery-center estimate of 3/298, approximately 1%, among developmental-delay exomes reflects highly selected referral ascertainment and must not be interpreted as population prevalence. (kennedy2019kat6asyndromegenotype–phenotype pages 1-2, liu2024kat6adeficiencyimpairs pages 1-2, arboleda2015denovononsense pages 6-7, weber2023thehistoneacetyltransferase pages 1-2)

Population prevalence, birth incidence, and carrier frequency remain unknown.

10. Diagnostics

Clinical recognition

Clinical suspicion should arise with global developmental delay—especially profound expressive speech delay—plus hypotonia, feeding/GI problems, a broad or bulbous nose with thin upper lip, low-set ears, eye findings, microcephaly, or congenital heart disease. No purely clinical diagnostic criteria are sufficiently specific; molecular confirmation is required.

Recommended genetic approach

1. Trio WES or WGS is the preferred broad approach for an undiagnosed syndromic neurodevelopmental disorder. WES identified the original de novo variants; WGS diagnosed a severe case within four weeks and may detect structural, noncoding, or coverage-limited variants missed by exome sequencing. (lin2020diagnosisofarboledatham pages 1-3, arboleda2015denovononsense pages 1-2)
2. Neurodevelopmental/intellectual-disability or congenital-anomaly panels should include KAT6A and detect single-nucleotide variants and indels, with validated exon-level copy-number analysis.
3. Single-gene sequencing is suitable when the phenotype is strongly suggestive or for familial testing.
4. Confirm the variant and parental status by an orthogonal method such as Sanger sequencing where appropriate.
5. Interpret variants using ACMG/AMP criteria, population frequency, predicted loss of function, exon position/NMD, de novo status, phenotype, splicing assays, and functional or methylation evidence.
6. CMA remains useful when a copy-number disorder is suspected or sequencing is nondiagnostic. Routine karyotype/FISH, mitochondrial DNA testing, and repeat-expansion testing are not first-line ARTHS tests.

RNA sequencing can resolve suspected splice variants, while blood DNA-methylation profiling may support classification of uncertain KAT6A/KAT6B variants. Neither replaces primary DNA testing.

Baseline and surveillance evaluations

Recommended evaluations include developmental and speech-language assessment; feeding/swallowing and nutrition review; growth and head circumference; ECG and echocardiogram; ophthalmology; hearing; neurologic assessment with EEG when seizures are suspected; GI review for reflux, constipation, malrotation, or obstruction; musculoskeletal examination; and renal/genitourinary assessment guided by findings. Brain MRI is clinically indicated for seizures, abnormal neurologic progression, unusual head growth, or focal findings, not as a diagnostic biomarker. (bae2021identificationofa pages 5-6, kennedy2019kat6asyndromegenotype–phenotype pages 6-7)

Differential diagnosis

Important differentials include KAT6B-related Say–Barber–Biesecker–Young–Simpson/genitopatellar syndromes, BRPF1-related intellectual developmental disorder with dysmorphic facies and ptosis, Wiedemann–Steiner syndrome, Kabuki syndrome, Coffin–Siris spectrum, Cornelia de Lange spectrum, Rubinstein–Taybi syndrome, CDK13-related disorder, and other monogenic chromatinopathies. Distinction generally requires genomic testing because ID, speech delay, hypotonia, feeding problems, heart defects, and dysmorphism overlap.

Population newborn screening is unavailable. Cascade testing is appropriate after a molecular diagnosis; prenatal diagnosis and preimplantation genetic testing are technically possible when the familial variant is known.

11. Outcome and prognosis

No reliable 5- or 10-year survival rate, disease-specific mortality rate, or life-expectancy estimate exists. The 2019 cohort included adults up to age 32, showing survival into adulthood, but adult ascertainment is limited. (kennedy2019kat6asyndromegenotype–phenotype pages 1-2)

Morbidity is dominated by communication and intellectual disability, delayed motor and adaptive skills, feeding/GI problems, visual impairment, sleep disturbance, and congenital anomalies. Developmental skills may improve with therapy, but full recovery from the underlying neurodevelopmental disorder is not expected. Prognostic factors supported at group level include variant position—late truncations generally confer greater severity—and the burden of congenital heart, GI, feeding, neurologic, or orthopedic complications. Individual prediction remains imprecise because expressivity varies even among people with the same variant. (kennedy2019kat6asyndromegenotype–phenotype pages 8-9, arboleda2015denovononsense pages 6-7)

There is no validated circulating, imaging, electrophysiologic, or molecular prognostic biomarker. DNA methylation signatures are diagnostic/classification candidates rather than proven outcome biomarkers.

12. Treatment

Current clinical management

There is no approved disease-modifying pharmacotherapy, gene therapy, RNA therapy, or cell therapy. Care is multidisciplinary and phenotype-directed:

• early intervention, special education, neuropsychology, and behavioral support;
• intensive speech-language therapy, with sign language, picture systems, or speech-generating devices introduced early rather than waiting for speech to emerge;
• physical and occupational therapy for hypotonia, coordination, mobility, and adaptive skills;
• swallow/feeding therapy, nutritional support, reflux treatment, and enteral feeding when required;
• constipation therapy and urgent evaluation of bilious vomiting or obstructive symptoms;
• standard cardiology and cardiac-surgical care;
• ophthalmologic treatment of strabismus, refractive error, ptosis, and amblyopia risk;
• standard antiseizure therapy when epilepsy is confirmed;
• sleep assessment and treatment of specific contributors;
• orthopedic, craniofacial, dental, hearing, and genitourinary care as indicated. (bae2021identificationofa pages 5-6, bae2021identificationofa pages 6-7, kennedy2019kat6asyndromegenotype–phenotype pages 6-7)

Suggested MAXO annotations include genetic counseling, exome/genome sequencing, echocardiography, electrocardiography, ophthalmologic examination, developmental assessment, speech therapy, augmentative and alternative communication, physical therapy, occupational therapy, feeding therapy, enteral nutrition, laxative therapy, antiseizure pharmacotherapy, and corrective cardiac or craniofacial surgery.

Experimental strategies

Patient fibroblasts treated with pantothenate and L-carnitine showed increased histone acetylation, partial normalization of protein and transcriptomic patterns, and significantly improved bioenergetics. Direct abstract quote: “Pantothenate and L-carnitine treatment increased histone acetylation and partially corrected protein and transcriptomic expression patterns in mutant KAT6A cells.” [Munuera-Cabeza et al., published December 2022; DOI: https://doi.org/10.3390/genes13122300]. This was an in-vitro study of three patient cell lines, not a clinical trial; efficacy, dosing, safety, and developmental benefit in patients are unknown. (munueracabeza2022pantothenateandlcarnitine pages 1-2, munueracabeza2022pantothenateandlcarnitine pages 15-16)

Enhancing RSPO2/Wnt signaling rescued cognitive and synaptic deficits in mice, identifying a target rather than a ready treatment. Systemic Wnt activation has substantial developmental and oncogenic risks, and human translation will require tissue-specific delivery and extensive safety work. (liu2024kat6adeficiencyimpairs pages 8-9)

No disease-specific interventional ClinicalTrials.gov study was retrieved. There are therefore no evidence-based response rates, adverse-event profiles, combination regimens, or pharmacogenomic prescribing recommendations for ARTHS.

13. Prevention

Primary prevention by lifestyle modification or vaccination is not possible for a usually de novo genetic disorder. The principal preventive actions are reproductive and complication-focused:

• preconception and postdiagnostic genetic counseling;
• parental testing, with discussion of residual germline-mosaicism risk;
• prenatal diagnosis or PGT-M when a pathogenic familial variant is known;
• early molecular diagnosis and developmental intervention;
• baseline cardiac and eye assessment to prevent avoidable cardiac morbidity and amblyopia;
• feeding/swallowing assessment to reduce malnutrition and aspiration risk;
• proactive constipation treatment and recognition of bowel obstruction;
• seizure, sleep, orthopedic, and hearing surveillance according to symptoms.

No population carrier-screening or newborn-screening program is indicated by current evidence. Public-health sanitation, vector control, environmental remediation, vaccines, and antimicrobial prophylaxis are not disease-specific measures.

14. Other species and natural disease

No naturally occurring veterinary syndrome clearly orthologous to human ARTHS was identified, and there is no zoonotic or cross-species transmission. Relevant orthologues include mouse Kat6a and zebrafish kat6a; exact NCBI Gene and Taxon identifiers should be populated from current NCBI records. Standard taxonomy identifiers are Homo sapiens Taxon 9606, Mus musculus Taxon 10090, and Danio rerio Taxon 7955.

KAT6A’s chromatin, embryonic-development, hematopoietic, cardiac, craniofacial, and neural functions are evolutionarily conserved. Animal phenotypes are experimental genetic models rather than evidence of a recognized spontaneous livestock, companion-animal, or wildlife disease. (arboleda2015denovononsense pages 6-7, weber2023thehistoneacetyltransferase pages 1-2)

15. Model organisms and experimental systems

Mouse models

• Constitutive homozygous Kat6a loss: embryonic or perinatal lethal, with vascular/cardiac, gastrointestinal, skeletal, thymic/splenic, neural-stem-cell, and hematopoietic defects. This model demonstrates essential developmental functions but is more severe than the usual human heterozygous syndrome. (arboleda2015denovononsense pages 6-7)
• Kat6a+/− early-truncation model: approximately 50% hippocampal Kat6a expression, reduced body weight, and learning/memory abnormalities, modeling human haploinsufficiency.
• Excitatory-neuron conditional knockout: reproduces CA3-specific synaptic and memory deficits without requiring whole-organism loss.
• Rspo2 conditional knockout and AAV-RSPO2 rescue: establish pathway causality and demonstrate that selected postnatal neural deficits can be reversed in mice. (liu2024kat6adeficiencyimpairs pages 8-9, liu2024kat6adeficiencyimpairs pages 1-2)

Limitations include species differences, simplified alleles, incomplete modeling of late-truncating human variants, and inability of behavioral assays to reproduce human speech, language, congenital anomalies, and psychosocial outcomes.

Cellular and biochemical models

Patient dermal fibroblasts reproduce altered histone acetylation, p53-related transcription, mitochondrial dysfunction, and treatment-responsive molecular phenotypes. Their accessibility is an advantage, but they do not fully model developing neurons, cardiomyocytes, cranial neural crest, or gastrointestinal tissues. Recombinant-domain, DNA-binding, chromatin-immunoprecipitation, and genome-wide occupancy assays established direct KAT6A recruitment to unmethylated CpG islands. (munueracabeza2022pantothenateandlcarnitine pages 1-2, arboleda2015denovononsense pages 6-7, weber2023thehistoneacetyltransferase pages 1-2)

No mature ARTHS-specific iPSC-neuron, cerebral-organoid, or patient-derived cardiac-organoid platform was identified in the retrieved literature; these are logical priorities for variant-specific therapeutic testing.

Recent developments, 2023–2024

1. Chromatin targeting: KAT6A was shown to bind unmethylated CpG islands directly through an N-terminal winged-helix domain, clarifying how the enzyme reaches genomic targets [published online December 20, 2022; journal issue 2023; DOI: https://doi.org/10.1093/nar/gkac1188]. (weber2023thehistoneacetyltransferase pages 1-2)
2. DNA-methylation diagnostics: a 2023 study reported KAT6A/KAT6B episignatures as sensitive and specific biomarkers for variant detection/classification; direct review is needed for exact validation metrics [DOI: https://doi.org/10.2217/epi-2023-0079].
3. Brain mechanism and rescue: the 2024 Science Advances study localized a major cognitive mechanism to CA3 KAT6A–RSPO2–Wnt signaling and achieved AAV-RSPO2 rescue [DOI: https://doi.org/10.1126/sciadv.adm9326]. (liu2024kat6adeficiencyimpairs pages 8-9, liu2024kat6adeficiencyimpairs pages 1-2)
4. Phenotypic expansion: 2024 reports added prenatal/fetal observations, including fetal hepatic calcification, and additional Asian cases, but these remain isolated observations rather than established screening markers [DOIs: https://doi.org/10.1016/j.ejmg.2023.104906 and https://doi.org/10.1002/mgg3.2420].
5. Clinical implementation: multidisciplinary chromatinopathy clinics increasingly integrate genomic sequencing, DNA-methylation profiling, anticipatory surveillance, and structured neurodevelopmental care; however, controlled ARTHS treatment trials remain absent.

Evidence assessment and major gaps

The gene–disease relationship and core phenotype are strongly supported by repeated de novo variants, recurrence, variant enrichment, and consistent human phenotypes. Genotype–phenotype correlation is moderately strong but subject to ascertainment and incomplete standardized testing. Cellular acetylation and metabolic abnormalities have direct human in-vitro support but small sample sizes. The CA3 RSPO2/Wnt mechanism has unusually strong preclinical causal evidence—including conditional genetics and rescue—but has not been demonstrated in human brain tissue or clinical intervention.

Priority gaps are population prevalence, adult natural history, formal adaptive and quality-of-life trajectories, penetrance of nontruncating variants, systematic immune/hematologic surveillance data, human neuronal and organoid models, validated longitudinal biomarkers, and controlled therapeutic trials. Consequently, experimental supplements or pathway-directed interventions should not be represented as established therapy.

References

1. (kennedy2019kat6asyndromegenotype–phenotype pages 8-9): Joanna Kennedy, David Goudie, Edward Blair, Kate Chandler, Shelagh Joss, Victoria McKay, Andrew Green, Ruth Armstrong, Melissa Lees, Benjamin Kamien, Bruce Hopper, Tiong Yang Tan, Patrick Yap, Zornitza Stark, Nobuhiko Okamoto, Noriko Miyake, Naomichi Matsumoto, Ellen Macnamara, Jennifer L. Murphy, Elizabeth McCormick, Hakon Hakonarson, Marni J. Falk, Dong Li, Patrick Blackburn, Eric Klee, Dusica Babovic-Vuksanovic, Susan Schelley, Louanne Hudgins, Sarina Kant, Bertrand Isidor, Benjamin Cogne, Kimberley Bradbury, Mark Williams, Chirag Patel, Helen Heussler, Celia Duff-Farrier, Phillis Lakeman, Ingrid Scurr, Usha Kini, Mariet Elting, Margot Reijnders, Janneke Schuurs-Hoeijmakers, Mohamed Wafik, Anne Blomhoff, Claudia A.L. Ruivenkamp, Esther Nibbeling, Alexander J.M. Dingemans, Emilie D. Douine, Stanley F. Nelson, Maja Hempel, Tatjana Bierhals, Davor Lessel, Jessika Johannsen, Valerie A. Arboleda, and Ruth Newbury-Ecob. Kat6a syndrome: genotype–phenotype correlation in 76 patients with pathogenic kat6a variants. Genetics in Medicine, 21:850-860, Apr 2019. URL: https://doi.org/10.1038/s41436-018-0259-2, doi:10.1038/s41436-018-0259-2. This article has 134 citations and is from a highest quality peer-reviewed journal.

2. (kennedy2019kat6asyndromegenotype–phenotype pages 1-2): Joanna Kennedy, David Goudie, Edward Blair, Kate Chandler, Shelagh Joss, Victoria McKay, Andrew Green, Ruth Armstrong, Melissa Lees, Benjamin Kamien, Bruce Hopper, Tiong Yang Tan, Patrick Yap, Zornitza Stark, Nobuhiko Okamoto, Noriko Miyake, Naomichi Matsumoto, Ellen Macnamara, Jennifer L. Murphy, Elizabeth McCormick, Hakon Hakonarson, Marni J. Falk, Dong Li, Patrick Blackburn, Eric Klee, Dusica Babovic-Vuksanovic, Susan Schelley, Louanne Hudgins, Sarina Kant, Bertrand Isidor, Benjamin Cogne, Kimberley Bradbury, Mark Williams, Chirag Patel, Helen Heussler, Celia Duff-Farrier, Phillis Lakeman, Ingrid Scurr, Usha Kini, Mariet Elting, Margot Reijnders, Janneke Schuurs-Hoeijmakers, Mohamed Wafik, Anne Blomhoff, Claudia A.L. Ruivenkamp, Esther Nibbeling, Alexander J.M. Dingemans, Emilie D. Douine, Stanley F. Nelson, Maja Hempel, Tatjana Bierhals, Davor Lessel, Jessika Johannsen, Valerie A. Arboleda, and Ruth Newbury-Ecob. Kat6a syndrome: genotype–phenotype correlation in 76 patients with pathogenic kat6a variants. Genetics in Medicine, 21:850-860, Apr 2019. URL: https://doi.org/10.1038/s41436-018-0259-2, doi:10.1038/s41436-018-0259-2. This article has 134 citations and is from a highest quality peer-reviewed journal.

3. (liu2024kat6adeficiencyimpairs pages 8-9): Yongqing Liu, Minghua Fan, Junhua Yang, Ljubica Mihaljević, Kevin Hong Chen, Yingzhi Ye, Shuying Sun, and Zhaozhu Qiu. Kat6a deficiency impairs cognitive functions through suppressing rspo2/wnt signaling in hippocampal ca3. Science Advances, May 2024. URL: https://doi.org/10.1126/sciadv.adm9326, doi:10.1126/sciadv.adm9326. This article has 20 citations and is from a highest quality peer-reviewed journal.

4. (liu2024kat6adeficiencyimpairs pages 1-2): Yongqing Liu, Minghua Fan, Junhua Yang, Ljubica Mihaljević, Kevin Hong Chen, Yingzhi Ye, Shuying Sun, and Zhaozhu Qiu. Kat6a deficiency impairs cognitive functions through suppressing rspo2/wnt signaling in hippocampal ca3. Science Advances, May 2024. URL: https://doi.org/10.1126/sciadv.adm9326, doi:10.1126/sciadv.adm9326. This article has 20 citations and is from a highest quality peer-reviewed journal.

5. (bae2021identificationofa pages 1-2): Soyoung Bae, Aram Yang, Jinsup Kim, Hyun Ju Lee, and Hyun Kyung Park. Identification of a novel kat6a variant in an infant presenting with facial dysmorphism and developmental delay: a case report and literature review. BMC Medical Genomics, Dec 2021. URL: https://doi.org/10.1186/s12920-021-01148-x, doi:10.1186/s12920-021-01148-x. This article has 22 citations and is from a peer-reviewed journal.

6. (arboleda2015denovononsense pages 1-2): Valerie A. Arboleda, Hane Lee, Naghmeh Dorrani, Neda Zadeh, Mary Willis, Colleen Forsyth Macmurdo, Melanie A. Manning, Andrea Kwan, Louanne Hudgins, Florian Barthelemy, M. Carrie Miceli, Fabiola Quintero-Rivera, Sibel Kantarci, Samuel P. Strom, Joshua L. Deignan, Wayne W. Grody, Eric Vilain, and Stanley F. Nelson. De novo nonsense mutations in kat6a, a lysine acetyl-transferase gene, cause a syndrome including microcephaly and global developmental delay. American journal of human genetics, 96 3:498-506, Mar 2015. URL: https://doi.org/10.1016/j.ajhg.2015.01.017, doi:10.1016/j.ajhg.2015.01.017. This article has 172 citations and is from a highest quality peer-reviewed journal.

7. (OpenTargets Search: Arboleda-Tham syndrome-KAT6A): Open Targets Query (Arboleda-Tham syndrome-KAT6A, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

8. (munueracabeza2022pantothenateandlcarnitine pages 1-2): Manuel Munuera-Cabeza, Mónica Álvarez-Córdoba, Juan Suárez-Rivero, Suleva Povea-Cabello, Irene Villalón-García, Marta Talaverón-Rey, Alejandra Suárez-Carrillo, Diana Reche-López, Paula Cilleros-Holgado, Rocío Piñero-Pérez, and José Sánchez-Alcázar. Pantothenate and l-carnitine supplementation improves pathological alterations in cellular models of kat6a syndrome. Genes, 13:2300, Dec 2022. URL: https://doi.org/10.3390/genes13122300, doi:10.3390/genes13122300. This article has 6 citations.

9. (lin2020diagnosisofarboledatham pages 3-4): Yung-Feng Lin, Tzu-Ching Lin, Ralph Kirby, Hui-Ying Weng, Yen-Ming Liu, Dau-Ming Niu, Shih-Feng Tsai, and Chia-Feng Yang. Diagnosis of arboleda-tham syndrome by whole genome sequencing in an asian boy with severe developmental delay. Molecular Genetics and Metabolism Reports, 25:100686, Dec 2020. URL: https://doi.org/10.1016/j.ymgmr.2020.100686, doi:10.1016/j.ymgmr.2020.100686. This article has 22 citations.

10. (kennedy2019kat6asyndromegenotype–phenotype pages 2-3): Joanna Kennedy, David Goudie, Edward Blair, Kate Chandler, Shelagh Joss, Victoria McKay, Andrew Green, Ruth Armstrong, Melissa Lees, Benjamin Kamien, Bruce Hopper, Tiong Yang Tan, Patrick Yap, Zornitza Stark, Nobuhiko Okamoto, Noriko Miyake, Naomichi Matsumoto, Ellen Macnamara, Jennifer L. Murphy, Elizabeth McCormick, Hakon Hakonarson, Marni J. Falk, Dong Li, Patrick Blackburn, Eric Klee, Dusica Babovic-Vuksanovic, Susan Schelley, Louanne Hudgins, Sarina Kant, Bertrand Isidor, Benjamin Cogne, Kimberley Bradbury, Mark Williams, Chirag Patel, Helen Heussler, Celia Duff-Farrier, Phillis Lakeman, Ingrid Scurr, Usha Kini, Mariet Elting, Margot Reijnders, Janneke Schuurs-Hoeijmakers, Mohamed Wafik, Anne Blomhoff, Claudia A.L. Ruivenkamp, Esther Nibbeling, Alexander J.M. Dingemans, Emilie D. Douine, Stanley F. Nelson, Maja Hempel, Tatjana Bierhals, Davor Lessel, Jessika Johannsen, Valerie A. Arboleda, and Ruth Newbury-Ecob. Kat6a syndrome: genotype–phenotype correlation in 76 patients with pathogenic kat6a variants. Genetics in Medicine, 21:850-860, Apr 2019. URL: https://doi.org/10.1038/s41436-018-0259-2, doi:10.1038/s41436-018-0259-2. This article has 134 citations and is from a highest quality peer-reviewed journal.

11. (urreizti2020fivenewcases pages 7-8): Roser Urreizti, Estrella Lopez-Martin, Antonio Martinez-Monseny, Montse Pujadas, Laura Castilla-Vallmanya, Luis Alberto Pérez-Jurado, Mercedes Serrano, Daniel Natera-de Benito, Beatriz Martínez-Delgado, Manuel Posada-de-la-Paz, Javier Alonso, Purificación Marin-Reina, Mar O’Callaghan, Daniel Grinberg, Eva Bermejo-Sánchez, and Susanna Balcells. Five new cases of syndromic intellectual disability due to kat6a mutations: widening the molecular and clinical spectrum. Orphanet Journal of Rare Diseases, Feb 2020. URL: https://doi.org/10.1186/s13023-020-1317-9, doi:10.1186/s13023-020-1317-9. This article has 48 citations and is from a peer-reviewed journal.

12. (kennedy2019kat6asyndromegenotype–phenotype pages 6-7): Joanna Kennedy, David Goudie, Edward Blair, Kate Chandler, Shelagh Joss, Victoria McKay, Andrew Green, Ruth Armstrong, Melissa Lees, Benjamin Kamien, Bruce Hopper, Tiong Yang Tan, Patrick Yap, Zornitza Stark, Nobuhiko Okamoto, Noriko Miyake, Naomichi Matsumoto, Ellen Macnamara, Jennifer L. Murphy, Elizabeth McCormick, Hakon Hakonarson, Marni J. Falk, Dong Li, Patrick Blackburn, Eric Klee, Dusica Babovic-Vuksanovic, Susan Schelley, Louanne Hudgins, Sarina Kant, Bertrand Isidor, Benjamin Cogne, Kimberley Bradbury, Mark Williams, Chirag Patel, Helen Heussler, Celia Duff-Farrier, Phillis Lakeman, Ingrid Scurr, Usha Kini, Mariet Elting, Margot Reijnders, Janneke Schuurs-Hoeijmakers, Mohamed Wafik, Anne Blomhoff, Claudia A.L. Ruivenkamp, Esther Nibbeling, Alexander J.M. Dingemans, Emilie D. Douine, Stanley F. Nelson, Maja Hempel, Tatjana Bierhals, Davor Lessel, Jessika Johannsen, Valerie A. Arboleda, and Ruth Newbury-Ecob. Kat6a syndrome: genotype–phenotype correlation in 76 patients with pathogenic kat6a variants. Genetics in Medicine, 21:850-860, Apr 2019. URL: https://doi.org/10.1038/s41436-018-0259-2, doi:10.1038/s41436-018-0259-2. This article has 134 citations and is from a highest quality peer-reviewed journal.

13. (bae2021identificationofa pages 5-6): Soyoung Bae, Aram Yang, Jinsup Kim, Hyun Ju Lee, and Hyun Kyung Park. Identification of a novel kat6a variant in an infant presenting with facial dysmorphism and developmental delay: a case report and literature review. BMC Medical Genomics, Dec 2021. URL: https://doi.org/10.1186/s12920-021-01148-x, doi:10.1186/s12920-021-01148-x. This article has 22 citations and is from a peer-reviewed journal.

14. (urreizti2020fivenewcases pages 6-7): Roser Urreizti, Estrella Lopez-Martin, Antonio Martinez-Monseny, Montse Pujadas, Laura Castilla-Vallmanya, Luis Alberto Pérez-Jurado, Mercedes Serrano, Daniel Natera-de Benito, Beatriz Martínez-Delgado, Manuel Posada-de-la-Paz, Javier Alonso, Purificación Marin-Reina, Mar O’Callaghan, Daniel Grinberg, Eva Bermejo-Sánchez, and Susanna Balcells. Five new cases of syndromic intellectual disability due to kat6a mutations: widening the molecular and clinical spectrum. Orphanet Journal of Rare Diseases, Feb 2020. URL: https://doi.org/10.1186/s13023-020-1317-9, doi:10.1186/s13023-020-1317-9. This article has 48 citations and is from a peer-reviewed journal.

15. (arboleda2015denovononsense pages 6-7): Valerie A. Arboleda, Hane Lee, Naghmeh Dorrani, Neda Zadeh, Mary Willis, Colleen Forsyth Macmurdo, Melanie A. Manning, Andrea Kwan, Louanne Hudgins, Florian Barthelemy, M. Carrie Miceli, Fabiola Quintero-Rivera, Sibel Kantarci, Samuel P. Strom, Joshua L. Deignan, Wayne W. Grody, Eric Vilain, and Stanley F. Nelson. De novo nonsense mutations in kat6a, a lysine acetyl-transferase gene, cause a syndrome including microcephaly and global developmental delay. American journal of human genetics, 96 3:498-506, Mar 2015. URL: https://doi.org/10.1016/j.ajhg.2015.01.017, doi:10.1016/j.ajhg.2015.01.017. This article has 172 citations and is from a highest quality peer-reviewed journal.

16. (weber2023thehistoneacetyltransferase pages 1-2): Lisa Marie Weber, Yulin Jia, Bastian Stielow, Stephen S Gisselbrecht, Yinghua Cao, Yanpeng Ren, Iris Rohner, Jessica King, Elisabeth Rothman, Sabrina Fischer, Clara Simon, Ignasi Forné, Andrea Nist, Thorsten Stiewe, Martha L Bulyk, Zhanxin Wang, and Robert Liefke. The histone acetyltransferase kat6a is recruited to unmethylated cpg islands via a dna binding winged helix domain. Nucleic Acids Research, 51:574-594, Dec 2023. URL: https://doi.org/10.1093/nar/gkac1188, doi:10.1093/nar/gkac1188. This article has 44 citations and is from a highest quality peer-reviewed journal.

17. (munueracabeza2022pantothenateandlcarnitine pages 15-16): Manuel Munuera-Cabeza, Mónica Álvarez-Córdoba, Juan Suárez-Rivero, Suleva Povea-Cabello, Irene Villalón-García, Marta Talaverón-Rey, Alejandra Suárez-Carrillo, Diana Reche-López, Paula Cilleros-Holgado, Rocío Piñero-Pérez, and José Sánchez-Alcázar. Pantothenate and l-carnitine supplementation improves pathological alterations in cellular models of kat6a syndrome. Genes, 13:2300, Dec 2022. URL: https://doi.org/10.3390/genes13122300, doi:10.3390/genes13122300. This article has 6 citations.

18. (lin2020diagnosisofarboledatham pages 1-3): Yung-Feng Lin, Tzu-Ching Lin, Ralph Kirby, Hui-Ying Weng, Yen-Ming Liu, Dau-Ming Niu, Shih-Feng Tsai, and Chia-Feng Yang. Diagnosis of arboleda-tham syndrome by whole genome sequencing in an asian boy with severe developmental delay. Molecular Genetics and Metabolism Reports, 25:100686, Dec 2020. URL: https://doi.org/10.1016/j.ymgmr.2020.100686, doi:10.1016/j.ymgmr.2020.100686. This article has 22 citations.

19. (bae2021identificationofa pages 6-7): Soyoung Bae, Aram Yang, Jinsup Kim, Hyun Ju Lee, and Hyun Kyung Park. Identification of a novel kat6a variant in an infant presenting with facial dysmorphism and developmental delay: a case report and literature review. BMC Medical Genomics, Dec 2021. URL: https://doi.org/10.1186/s12920-021-01148-x, doi:10.1186/s12920-021-01148-x. This article has 22 citations and is from a peer-reviewed journal.

20. (kennedy2019kat6asyndromegenotype–phenotype pages 9-10): Joanna Kennedy, David Goudie, Edward Blair, Kate Chandler, Shelagh Joss, Victoria McKay, Andrew Green, Ruth Armstrong, Melissa Lees, Benjamin Kamien, Bruce Hopper, Tiong Yang Tan, Patrick Yap, Zornitza Stark, Nobuhiko Okamoto, Noriko Miyake, Naomichi Matsumoto, Ellen Macnamara, Jennifer L. Murphy, Elizabeth McCormick, Hakon Hakonarson, Marni J. Falk, Dong Li, Patrick Blackburn, Eric Klee, Dusica Babovic-Vuksanovic, Susan Schelley, Louanne Hudgins, Sarina Kant, Bertrand Isidor, Benjamin Cogne, Kimberley Bradbury, Mark Williams, Chirag Patel, Helen Heussler, Celia Duff-Farrier, Phillis Lakeman, Ingrid Scurr, Usha Kini, Mariet Elting, Margot Reijnders, Janneke Schuurs-Hoeijmakers, Mohamed Wafik, Anne Blomhoff, Claudia A.L. Ruivenkamp, Esther Nibbeling, Alexander J.M. Dingemans, Emilie D. Douine, Stanley F. Nelson, Maja Hempel, Tatjana Bierhals, Davor Lessel, Jessika Johannsen, Valerie A. Arboleda, and Ruth Newbury-Ecob. Kat6a syndrome: genotype–phenotype correlation in 76 patients with pathogenic kat6a variants. Genetics in Medicine, 21:850-860, Apr 2019. URL: https://doi.org/10.1038/s41436-018-0259-2, doi:10.1038/s41436-018-0259-2. This article has 134 citations and is from a highest quality peer-reviewed journal.

Artifacts

• Edison artifact artifact-00